ClinicalTrials.gg
Drug

Renvistobart clinical trials

Also written BMS-986207.

studies test it
3
open now
0
in phase 3
0
first study started
2016

How each study uses renvistobart has had a first review. Readers can ask us to read every study one by one.Ask us to read each study

Approvals

The first approval found in each region, with its record

United States
Not in FDA's approval records
European Union
Not in EMA's list of EU-wide authorizations

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Development codes

BMS-986207
3

Studies by the year they started

3 studies that test it; most in 2016 (1)

Studies that test renvistobart, by start year
YearStudies
20161
20201
20221

By phase

A phase 1/2 study counts in both.

Phase 1
2
Phase 2
3

What it is tested for

Each study’s main condition, where its own words name it, so a study counts once.

Who runs them

Industry 2 · Other 1

Bristol-Myers Squibb (2) · Multiple Myeloma Research Consortium (1)

Often tested with

Tested in the same studies.

Relatlimab (1)

Related medicines

As reviewed, each with the page that says it.

Studies

Open first, then newest update. How each study uses renvistobart has had a first review, but it may not be perfect: check the study record before relying on it for anything important, and report a problem from its row. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.

Testing it · 3

Tested with established drugs · 2 — they are given beside it
Tested in a combination · 1 — another drug in the study is under test too

Codes

What other systems call renvistobart · ClinicalTrials.gg INT015572

  • UNII (FDA) 81J55YFQ16RENVISTOBARTOne source FDA
  • NCI Thesaurus C131907RenvistobartOne source FDA

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.

Start the discussion